[{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"a6d31c69-7c36-43a0-bc25-c25fb37e0176","acronym":"AGA TKI NSCLC","url":"https://clinicaltrials.gov/study/NCT07158840","created_at":"2025-09-13T08:44:13.914Z","updated_at":"2025-09-13T08:44:13.914Z","phase":"Phase 2","brief_title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","source_id_and_acronym":"NCT07158840 - AGA TKI NSCLC","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-09-08"},{"id":"251e3807-7c32-48ca-b5d8-dd58192012fb","acronym":"DIVON","url":"https://clinicaltrials.gov/study/NCT06957561","created_at":"2025-09-07T01:29:15.570Z","updated_at":"2025-09-07T01:29:15.570Z","phase":"Phase 1/2","brief_title":"Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer","source_id_and_acronym":"NCT06957561 - DIVON","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-05-04"},{"id":"bb6bfd1b-2fa4-443f-a449-16c91a04c63d","acronym":"HARMONi-3","url":"https://clinicaltrials.gov/study/NCT05899608","created_at":"2023-06-12T15:08:54.174Z","updated_at":"2025-02-25T13:55:16.855Z","phase":"Phase 3","brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","source_id_and_acronym":"NCT05899608 - HARMONi-3","lead_sponsor":"Summit Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 1080","initiation":"Initiation: 10/26/2023","start_date":" 10/26/2023","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-20"},{"id":"725d2049-0175-4171-b6e4-a461d540cccf","acronym":"HARMONi-7","url":"https://clinicaltrials.gov/study/NCT06767514","created_at":"2025-02-25T19:17:49.044Z","updated_at":"2025-02-25T19:17:49.044Z","phase":"Phase 3","brief_title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","source_id_and_acronym":"NCT06767514 - HARMONi-7","lead_sponsor":"Summit Therapeutics","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 780","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2025-01-20"},{"id":"01d5a833-1fd0-43f1-8b08-9b99a1ad4838","acronym":"","url":"https://clinicaltrials.gov/study/NCT05296278","created_at":"2022-03-26T00:54:56.650Z","updated_at":"2024-07-02T16:35:23.954Z","phase":"Phase 2","brief_title":"Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC","source_id_and_acronym":"NCT05296278","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Alecensa (alectinib) • Lenvima (lenvatinib) • Yidafan (ivonescimab) • IBI-323 • simridarlimab (IBI-322)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-10"},{"id":"358ec232-22b9-43f3-893c-ffddbf8c3f3c","acronym":"AK112-303","url":"https://clinicaltrials.gov/study/NCT05499390","created_at":"2022-08-14T17:58:07.092Z","updated_at":"2024-07-02T16:35:36.195Z","phase":"Phase 3","brief_title":"AK112 in Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05499390 - AK112-303","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yidafan (ivonescimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 398","initiation":"Initiation: 11/09/2022","start_date":" 11/09/2022","primary_txt":" Primary completion: 06/17/2024","primary_completion_date":" 06/17/2024","study_txt":" Completion: 06/17/2025","study_completion_date":" 06/17/2025","last_update_posted":"2023-09-21"},{"id":"e7b2becf-d2ea-4e6b-ac32-69be2d3a9278","acronym":"AK112-306","url":"https://clinicaltrials.gov/study/NCT05840016","created_at":"2023-05-03T15:04:35.945Z","updated_at":"2024-07-02T16:35:39.169Z","phase":"Phase 3","brief_title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05840016 - AK112-306","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Tevimbra (tislelizumab-jsgr) • Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 08/17/2023","start_date":" 08/17/2023","primary_txt":" Primary completion: 12/20/2024","primary_completion_date":" 12/20/2024","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2023-08-23"},{"id":"e719e53a-348e-4f61-a2ec-8427efdc6994","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846867","created_at":"2023-05-06T14:04:17.161Z","updated_at":"2024-07-02T16:35:48.741Z","phase":"Phase 1/2","brief_title":"Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients","source_id_and_acronym":"NCT05846867","lead_sponsor":"Akeso","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • MSH6 expression","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Yidafan (ivonescimab) • drebuxelimab (AK119)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 05/10/2024","primary_completion_date":" 05/10/2024","study_txt":" Completion: 07/10/2025","study_completion_date":" 07/10/2025","last_update_posted":"2023-05-08"},{"id":"e399a153-e7cd-4e15-a2d8-474eafc401eb","acronym":"AK112-203","url":"https://clinicaltrials.gov/study/NCT04870177","created_at":"2021-05-03T12:04:40.133Z","updated_at":"2024-07-02T16:36:02.637Z","phase":"Phase 2","brief_title":"Study of AK112 in the Treatment of Advanced Gynecological Tumors","source_id_and_acronym":"NCT04870177 - AK112-203","lead_sponsor":"Akeso","biomarkers":" PD-L1 • BRCA1 • BRCA2 • MSI","pipe":" | ","alterations":" PD-L1 expression • BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • BRCA2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRCA2 mutation • BRCA1 mutation • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 03/16/2021","start_date":" 03/16/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-10-11"},{"id":"f818104e-6009-433f-abd1-d941eabe0b84","acronym":"AK112-202","url":"https://clinicaltrials.gov/study/NCT04900363","created_at":"2021-05-25T18:52:34.886Z","updated_at":"2024-07-02T16:36:02.703Z","phase":"Phase 1/2","brief_title":"A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC","source_id_and_acronym":"NCT04900363 - AK112-202","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yidafan (ivonescimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-10-11"},{"id":"cf7c9bf8-9998-421c-af0f-232e1fae07bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05227664","created_at":"2022-02-12T13:52:34.003Z","updated_at":"2024-07-02T16:36:04.108Z","phase":"Phase 2","brief_title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05227664","lead_sponsor":"Akeso","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Yidafan (ivonescimab) • ligufalimab (AK117)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/23/2022","start_date":" 03/23/2022","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2022-09-12"},{"id":"726c31e3-f27c-4c7c-808b-3d3d8e64ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05229497","created_at":"2022-02-12T13:52:34.813Z","updated_at":"2024-07-02T16:36:10.621Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","source_id_and_acronym":"NCT05229497","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • 5-fluorouracil • Yidafan (ivonescimab) • ligufalimab (AK117)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 05/04/2022","start_date":" 05/04/2022","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2022-05-11"}]